May 30, 2024
DURHAM, N.C. , May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte , Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief...
May 13, 2024
DURHAM, N.C. , May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte , Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason , M.D., Ph.D., Founder, President, and Chief...
May 10, 2024
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024 - -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m....
Mar 22, 2024
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024 - -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024 - -Raised approximately $43.1 million in net proceeds from public offering of common stock- -Conference call and live...
Mar 01, 2024
DURHAM, N.C. , March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason , M.D., Ph.D., Founder, President, and Chief...
Displaying 1 - 10 of 116